CA2557520A1 - A method for stabilizing blood pressure in hemodialysis subjects - Google Patents
A method for stabilizing blood pressure in hemodialysis subjects Download PDFInfo
- Publication number
- CA2557520A1 CA2557520A1 CA002557520A CA2557520A CA2557520A1 CA 2557520 A1 CA2557520 A1 CA 2557520A1 CA 002557520 A CA002557520 A CA 002557520A CA 2557520 A CA2557520 A CA 2557520A CA 2557520 A1 CA2557520 A1 CA 2557520A1
- Authority
- CA
- Canada
- Prior art keywords
- receptor agonist
- blood pressure
- vasopressin
- subject
- hemodialysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
Abstract
The present invention provides a method for regulating blood pressure in a hemodialysis subject using a vasopressin receptor agonist, so as to facilitate removal of excessive extracellular fluid in the subject.
Claims (13)
1. A method for reducing excess extracellular fluid in a subject undergoing hemodialysis comprising administering a V-1 receptor agonist to the subject in an effective amount and thereby maintaining blood pressure during hemodialysis in order to facilitate reducing excess extracellular fluid in the subject.
2. A method for stabilizing high blood pressure between hemodialysis treatments in a subject undergoing hemodialysis by reducing excess extracellular fluid by the method of claim 1.
3. A method for inhibiting interdialytic hypertension by regulating blood pressure by the method of claim 2.
4. A method for inhibiting intradialytic hypotension by regulating blood pressure by the method of claim 1.
5. The method of claim 1, wherein the V-1 receptor agonist is arginine vasopressin.
6. The method of claim 1, wherein the V-1 receptor agonist is lysine vasopressin.
7. The method of claim 1, wherein the V-1 receptor agonist is terlipressin.
8. The method of claim 1, wherein the V-1 receptor agonist is octapressin
9. The method of claim 1, wherein the V-1 receptor agonist is ornipressin
10. The method of claim 1, wherein the V-1 receptor agonist is an organic molecule selected from the group consisting of 3-beta-(2-thienyl)-L-alanine)-8-lysine-vasopressin, N-alpha-glycyl-glycyl-glycyl-[8-lysine]-vasopressin, and 1-deamino-6-carba-[8-arginine]-vasopressin.
11. The method of claim 1, wherein the effective amount of the V-1 receptor agonist is in a range of about 0.05 milliunits/kg/minute - 2.0 milliunits/kg/hr.
12. The method of claim 1, wherein the effective amount of the V-1 receptor agonist is about 0.3 milliunits/kg/minute.
13. The method of claim 1, wherein the subject is a human, non-human primate, rabbit, sheep, rat, dog, cat, pig, or mouse.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45060903P | 2003-02-26 | 2003-02-26 | |
US60/450,609 | 2003-02-26 | ||
PCT/US2004/006029 WO2004075783A2 (en) | 2003-02-26 | 2004-02-26 | A method for stabilizing blood pressure in hemodialysis subjects |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2557520A1 true CA2557520A1 (en) | 2004-09-10 |
CA2557520C CA2557520C (en) | 2011-09-13 |
Family
ID=32927674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2557520A Expired - Lifetime CA2557520C (en) | 2003-02-26 | 2004-02-26 | A method for stabilizing blood pressure in hemodialysis subjects |
Country Status (3)
Country | Link |
---|---|
US (2) | US7183255B2 (en) |
CA (1) | CA2557520C (en) |
WO (1) | WO2004075783A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004075783A2 (en) * | 2003-02-26 | 2004-09-10 | Landry Donald W | A method for stabilizing blood pressure in hemodialysis subjects |
JO2937B1 (en) | 2004-08-11 | 2016-03-15 | فيرينغ.بي.في | Peptidic Vasopressin Receptor Agonists |
NZ569836A (en) * | 2006-02-10 | 2010-09-30 | Ferring Bv | Novel compounds |
US8222202B2 (en) * | 2006-02-13 | 2012-07-17 | Ferring B.V. | Use of peptidic vasopressin receptor agonists |
WO2009037586A2 (en) * | 2007-08-14 | 2009-03-26 | Ferring B.V. | Use of peptidic vasopressin receptor agonists |
WO2009045309A2 (en) * | 2007-09-28 | 2009-04-09 | Ferring B.V. | Use of v2 receptor antagonists in combination with vasopressinergic agonists |
US7879069B2 (en) * | 2007-10-26 | 2011-02-01 | Global Monitors, Inc. | Anti-pooling vest for patients undergoing hemodialysis and in critical care |
CA2761607C (en) | 2009-06-08 | 2018-09-04 | Yi-Qun Shi | Melanocortin receptor-specific peptides |
US9177129B2 (en) * | 2012-06-27 | 2015-11-03 | Intel Corporation | Devices, systems, and methods for monitoring and asserting trust level using persistent trust log |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE457055B (en) * | 1986-08-18 | 1988-11-28 | Ferring Ab | TOPIC RADIATION GEL FOR MUKOSA CONTAINING VARIETY CONDUCTIVE SUBSTANCES |
JPH09507867A (en) | 1994-11-17 | 1997-08-12 | バクスター、インターナショナル、インコーポレイテッド | Hemoglobin therapy in hemodialysis |
WO2004075783A2 (en) * | 2003-02-26 | 2004-09-10 | Landry Donald W | A method for stabilizing blood pressure in hemodialysis subjects |
-
2004
- 2004-02-26 WO PCT/US2004/006029 patent/WO2004075783A2/en active Application Filing
- 2004-02-26 US US10/789,548 patent/US7183255B2/en not_active Expired - Lifetime
- 2004-02-26 CA CA2557520A patent/CA2557520C/en not_active Expired - Lifetime
-
2007
- 2007-02-26 US US11/710,754 patent/US20070213259A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2557520C (en) | 2011-09-13 |
US7183255B2 (en) | 2007-02-27 |
WO2004075783A2 (en) | 2004-09-10 |
US20040229798A1 (en) | 2004-11-18 |
US20070213259A1 (en) | 2007-09-13 |
WO2004075783A3 (en) | 2004-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Matsumura et al. | Angiotensin II acts at AT1receptors in the nucleus of the solitary tract to attenuate the baroreceptor reflex | |
Machado et al. | Mechanisms of angiotensin-(1–7)-induced inhibition of angiogenesis | |
Cesari et al. | Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases | |
CA2557520A1 (en) | A method for stabilizing blood pressure in hemodialysis subjects | |
ATE390142T1 (en) | SYNERGISTIC COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS | |
ATE462427T1 (en) | USE OF TREPROSTINIL TO TREAT NEUROPATHIC DIABETIC FOOT ULCERS | |
MX2009004424A (en) | Neuronal exocytosis inhibiting peptides. | |
DK0738262T3 (en) | New Heterocyclic Compounds | |
RU2661109C2 (en) | Angiotensin in treating brain conditions | |
BR0310047A (en) | 8-azaprostaglandin analogues as agents for intraocular pressure decrease | |
Wright et al. | Aminopeptidase-induced elevations and reductions in blood pressure in the spontaneously hypertensive rat | |
Sharma et al. | Nitric oxide inhibits the expression of AT1 receptors in neurons | |
WO2003093313A3 (en) | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein | |
NZ610732A (en) | Novel angiotensin type 2 (at2) receptor agonists and uses thereof | |
DD158238A5 (en) | METHOD FOR PRODUCING A NEW INHIBITOR FOR ANGIOTENSE CONVERTING ENZYME | |
DE602004002394D1 (en) | (3-ä3 - '(2,4-BIS-TRIFLUOROMETHYL-BENZYL) - (5-ETHYL-PYRIMIDIN-2-YL) -AMINOÜ-PROPOXYU-PHENYL) ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHOD FOR THE TREATMENT OF METABOLIC DISORDERS | |
DE60219614D1 (en) | 3, 7 THIAPROSTANSÄUREDERIVATE AS A MEANS FOR THE REDUCTION OF THE AUGENINNENDRUCKES | |
ATE360424T1 (en) | 2,3,4,5-TETRAHYDROBENZO[FÖ]1,4ÖOXAZEPINE-5-CARBONIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S | |
KR20160016872A (en) | Angiotensin peptides in treating marfan syndrome and related disorders | |
Abramov et al. | Regulation of feeding by galnon | |
Nakamura et al. | Cardiovascular responses to microinjections of urocortin 3 into the nucleus tractus solitarius of the rat | |
IL117816A0 (en) | N-subsituted azaheterocyclic compounds their preparation and pharmaceutical compositions containing them | |
Pandey et al. | Protective effects of aprotinin on respiratory and cardiac abnormalities induced by Mesobuthus tamulus venom in adult rats | |
Wright et al. | Use of aminopeptidase M as a hypotensive agent in spontaneously hypertensive rats | |
CN1322212A (en) | Neuropeptide Y agaonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |